Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C-SSM-VIP is a preclinical-stage, actively targeted nanomedicine formulation consisting of curcumin encapsulated within sterically stabilized phospholipid nanomicelles (SSM) that are surface-conjugated with vasoactive intestinal peptide (VIP). Developed at the University of Illinois at Chicago, this formulation is designed to target breast cancer stem cells (CSCs), which overexpress VIP receptors. By binding to these receptors, C-SSM-VIP undergoes receptor-mediated endocytosis, enhancing the intracellular delivery and bioavailability of curcumin. Curcumin then acts to inhibit key cancer stem cell survival and self-renewal pathways, offering a potential therapeutic strategy to prevent breast cancer recurrence and metastasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on C-SSM-VIP.